Track topics on Twitter Track topics that are important to you
Tosk, Inc. announced today that it has received a two-year, $2 million Phase II SIBR grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug research and ...
AzurRx BioPharma plans to raise $50m through a public offering of securities. The company intends to issue the securities periodically in...Read More... The post Deals this week: AzurRx BioPharma, In...
Tosk was founded in 1998 to discover new drugs for genetic diseases and cancer. The original technology, in part licensed from Stanford University,StealthGene and Targeted Gene Delivery technologies. ...
Neurodegenerative diseases and cancer. The Company’s AON QTS technology not only targets the neurodegeneration process, which will allow discovered drugs to be applicable to a variety of AON disease...
We have published hundreds of Tosk, Inc. news stories on BioPortfolio along with dozens of Tosk, Inc. Clinical Trials and PubMed Articles about Tosk, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tosk, Inc. Companies in our database. You can also find out about relevant Tosk, Inc. Drugs and Medications on this site too.